T细胞受体工程化T细胞的临床应用及肿瘤特异性抗原和T细胞受体的筛选策略  

Clinical Application of T Cell Receptor-Engineered T Cells and the Screening Strategy of Tumor-Specific Antigen and T Cell Receptors

作　　者：黄倩茹 朱一成 李扬扬 李斌[1] HUANG Qianru;ZHU Yicheng;LI Yangyang;LI Bin(Shanghai Jiao Tong University School of Medicine,Shanghai Institute of Immunology,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院上海市免疫学研究所,上海200025

出　　处：《药学进展》2021年第8期597-607,共11页Progress in Pharmaceutical Sciences

基　　金：国家杰出青年科学基金(No.31525008),国家自然科学基金(No.81830051)。

摘　　要：利用靶向具有免疫原性的肿瘤抗原的T细胞受体工程化T细胞(T cell receptor-engineered T cells,TCR-T)进行过继性细胞免疫治疗,可有效清除肿瘤且无明显副作用,实现令人欣喜的治疗效果。但该治疗领域还处在起步阶段,如何筛选肿瘤特异性抗原及其对应的T细胞受体(T cell receptor,TCR)极具挑战性。综述TCR-T临床试验项目研究进展,总结神经网络计算机学习在辅助发现潜在抗原和候选TCR方面的发展情况,并介绍近年来基于多学科综合搭建的针对肿瘤特异性抗原及其对应TCR的不同筛选平台,以期为TCR-T应用范围的扩展提供新思路。Adoptive cell immunotherapy with T cell receptor-engineered T cells(TCR-T)targeting immunogenic tumor antigens can effectively kill tumors without obvious side reactions.However,this field is still in its infancy,with great challenges to how to screen tumorspecific antigens and their corresponding T cell receptors(TCRs).In this paper,the advances in research on current TCR-T clinical trials are reviewed,the development of machine learning involved in putative antigen and candidate TCR prediction is summarized,and different screening strategies for tumor-specific antigens and corresponding TCRs based on comprehensive studies are introduced,so as to provoke new insight for further development of TCR-T therapy.

关 键 词：过继性T细胞疗法 T细胞受体工程化T细胞 肿瘤抗原筛选 

分 类 号：Q789[生物学—分子生物学] R730.51[医药卫生—肿瘤]